Sprout Pharmaceuticals

Sprout Pharmaceuticals focuses on addressing Hypoactive Sexual Desire Disorder (HSDD) and low libido in women, providing a unique treatment option with their FDA-approved drug, Addyi. The company operates in the pharmaceutical industry, specifically targeting female sexual health, a market previously underserved. Sprout's business model involves the development, approval, and distribution of pharmaceutical products aimed at improving women's sexual function. Revenue is generated through the sales of Addyi, which has shown significant improvements in female sexual function, including arousal, desire, lubrication, satisfaction, and orgasm. The company serves women looking for solutions to sexual dysfunction, making their product both affordable and accessible. After being acquired by Valeant for $1 billion in 2015, Sprout was reestablished in 2017 with Cindy Eckert as CEO, continuing its mission to provide effective treatments for women. Keywords: HSDD, low libido, female sexual health, Addyi, FDA-approved, pharmaceutical, arousal, desire, satisfaction, Cindy Eckert.